Omeros Corporation Company Profile (NASDAQ:OMER)

About Omeros Corporation

Omeros Corporation logoOmeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement. Its clinical programs include Mannan-binding lectin-associated serine protease-2 (MASP-2) (OMS721)-Lectin Pathway Disorders; PDE10 (OMS824)-CNS Disorders; peroxisome proliferator-activated receptor gamma (PPARy) (OMS405)-Addiction, and OMS201-Urology. Its preclinical programs include phosphodiesterase 7 (PDE7) (OMS527), Plasmin (OMS616), MASP-3 (OMS906)-Alternative Pathway Disorders, GPR17-CNS Disorders, GPR101-Metabolic Disorders, GPR151-CNS Disorders, GPR161-Cancer, GPR174-Immune Disorders, GPR183-Skeletal and Infectious Diseases, GPCR Platform and Antibody Platform.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: OMER
  • CUSIP: 68214310
Key Metrics:
  • Previous Close: $8.72
  • 50 Day Moving Average: $10.17
  • 200 Day Moving Average: $11.46
  • 52-Week Range: $7.20 - $16.80
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -17.80
  • P/E Growth: -0.08
  • Market Cap: $342.63M
  • Outstanding Shares: 39,293,000
  • Beta: 2.49
  • Net Margins: -266.47%
  • Return on Assets: -137.99%
  • Debt-to-Equity Ratio: -1.43%
  • Current Ratio: 2.12%
  • Quick Ratio: 2.01%
Additional Links:
Companies Related to Omeros Corporation:

Analyst Ratings

Consensus Ratings for Omeros Corporation (NASDAQ:OMER) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $35.09 (302.41% upside)

Analysts' Ratings History for Omeros Corporation (NASDAQ:OMER)
DateFirmActionRatingPrice TargetDetails
10/21/2016WedbushReiterated RatingOutperform$56.00View Rating Details
10/18/2016FBR & CoReiterated RatingOutperform$38.00View Rating Details
10/18/2016Maxim GroupReiterated RatingBuy$19.00View Rating Details
10/17/2016Cantor FitzgeraldReiterated RatingBuy$21.00View Rating Details
10/17/2016WBB SecuritiesReiterated RatingBuy$75.00View Rating Details
10/17/2016S&P Equity ResearchBoost Price Target$7.65 -> $8.63View Rating Details
3/2/2016Needham & Company LLCLower Price TargetBuy$30.00 -> $28.00View Rating Details
8/19/2015Roth CapitalReiterated RatingBuy$38.00View Rating Details
8/18/2015Cowen and CompanyReiterated RatingOutperformView Rating Details
8/11/2015MLV & Co.Reiterated RatingBuy$38.00View Rating Details
(Data available from 10/24/2014 forward)


Earnings History for Omeros Corporation (NASDAQ:OMER)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2016Q216($0.50)($0.32)$9.80 million$10.00 millionViewListenView Earnings Details
5/10/2016Q116($0.43)($0.54)$8.79 million$7.40 millionViewListenView Earnings Details
3/8/2016Q415($0.53)($0.52)$5.35 million$6.66 millionViewListenView Earnings Details
11/9/2015Q315($0.47)($0.46)$7.97 million$3.30 millionViewListenView Earnings Details
8/10/2015Q215($0.56)($0.44)$2.86 million$3.20 millionViewListenView Earnings Details
5/11/2015Q115($0.63)($0.51)$0.15 million$0.39 millionViewListenView Earnings Details
3/16/2015Q4($0.62)($0.61)$0.15 million$0.18 millionViewListenView Earnings Details
11/10/2014Q114($0.59)($0.54)$0.43 million$0.21 millionViewN/AView Earnings Details
8/11/2014Q2($0.56)($0.53)$0.37 million$0.45 millionViewN/AView Earnings Details
5/12/2014Q1($0.45)($0.45)$0.45 million$0.10 millionViewN/AView Earnings Details
3/13/2014Q413($0.38)($0.05)$0.17 million$1.70 millionViewN/AView Earnings Details
11/7/2013Q313($0.44)($0.46)$0.14 million$0.20 millionViewN/AView Earnings Details
8/9/2013Q213($0.38)($0.48)$1.19 million$0.14 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.39)($0.40)$1.39 million$1.10 millionViewN/AView Earnings Details
3/18/2013($0.35)($0.30)$1.49 million$1.58 millionViewN/AView Earnings Details
11/9/2012Q312($0.34)($0.51)$1.42 million$1.40 millionViewN/AView Earnings Details
8/7/2012($0.36)($0.38)ViewN/AView Earnings Details
11/8/2011($0.39)($0.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Omeros Corporation (NASDAQ:OMER)
Current Year EPS Consensus Estimate: $-1.55 EPS
Next Year EPS Consensus Estimate: $-0.49 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.52)($0.42)($0.47)
Q2 20163($0.52)($0.31)($0.43)
Q3 20163($0.31)($0.22)($0.27)
Q4 20163($0.33)($0.12)($0.22)
Q1 20171($0.14)($0.14)($0.14)
Q2 20171($0.02)($0.02)($0.02)
Q3 20171$0.11$0.11$0.11
Q4 20171$0.19$0.19$0.19
(Data provided by Zacks Investment Research)


Dividend History for Omeros Corporation (NASDAQ:OMER)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Omeros Corporation (NASDAQ:OMER)
Insider Ownership Percentage: 13.60%
Institutional Ownership Percentage: 48.04%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/15/2016Marcia S KelbonVPSell16,000$10.91$174,560.00View SEC Filing  
8/15/2016Marcia S KelbonVPSell15,900$11.56$183,804.00View SEC Filing  
7/15/2016Marcia S KelbonVPSell15,900$11.50$182,850.00View SEC Filing  
6/15/2016Marcia S KelbonVPSell15,900$11.42$181,578.00View SEC Filing  
5/16/2016Marcia S KelbonVPSell15,900$9.94$158,046.00View SEC Filing  
4/15/2016Marcia S KelbonVPSell15,900$15.18$241,362.00View SEC Filing  
3/24/2016Thomas J CableDirectorSell2,000$14.81$29,620.00View SEC Filing  
12/22/2015Marcia S. KelbonVPSell15,900$15.00$238,500.00View SEC Filing  
9/4/2015Peter A Md DemopulosDirectorBuy3,962$12.68$50,238.16View SEC Filing  
7/15/2015Thomas J CableDirectorSell2,000$18.78$37,560.00View SEC Filing  
3/24/2015Thomas J CableDirectorSell2,000$24.50$49,000.00View SEC Filing  
6/24/2014Peter A Md DemopulosDirectorBuy6,153$16.20$99,678.60View SEC Filing  
6/2/2014Thomas J CableDirectorSell5,000$11.80$59,000.00View SEC Filing  
7/3/2013Thomas J CableDirectorSell5,000$5.21$26,050.00View SEC Filing  
4/10/2013Thomas J CableDirectorSell5,000$3.98$19,900.00View SEC Filing  
1/4/2013Ray AspiriDirectorBuy40,000$5.72$228,800.00View SEC Filing  
1/3/2013Arnold C HanishDirectorBuy2,000$5.58$11,160.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Omeros Corporation (NASDAQ:OMER)
News IconOmeros Corporation's (OMER) “Outperform” Rating Reiterated at ... - DailyQuint (NASDAQ:OMER) - October 22 at 10:39 AM
News IconOmeros Corporation (OMER) Receives Outperform Rating from FBR & Co (NASDAQ:OMER) - October 21 at 6:39 PM logoOmeros: Upside/Risk With Orphan Drug Strategy - Seeking Alpha (NASDAQ:OMER) - October 21 at 10:05 AM
News IconBiotech Stocks Worth a Closer Look: Omeros Corporation (NASDAQ:OMER), Portola Pharmaceuticals, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:OMER) - October 20 at 6:55 PM logoCompany Update (NASDAQ:OMER): Omeros Corporation Announces Positive Data from OMS721 Phase 2 Trial in ... - Smarter Analyst (NASDAQ:OMER) - October 20 at 6:55 PM logoOmeros Stock Remains Higher On Promising Kidney Drug Trial Data (NASDAQ:OMER) - October 20 at 6:55 PM logoOmeros' OMS721 shows positive effect in mid-stage study in HSCT-associated small vessel blood clots; shares up 6% (NASDAQ:OMER) - October 20 at 12:46 PM
News IconBlog Coverage Omeros Announces Positive Results for Trials against Cocaine Use Disorder (NASDAQ:OMER) - October 20 at 12:26 PM logoBRIEF-Omeros Corp announces positive data from OMS721 phase 2 trial (NASDAQ:OMER) - October 20 at 12:26 PM logoOmeros Announces Positive Data from OMS721 Phase 2 Trial in Patients with Stem Cell Transplant-Associated Thrombotic Microangiopathy (NASDAQ:OMER) - October 20 at 12:26 PM
News IconConsensus Review & Target Check on Omeros Corporation (NASDAQ:OMER) - Recall News (NASDAQ:OMER) - October 19 at 6:56 PM logo16 Stocks Moving In Wednesday's Pre-Market Session - Benzinga (NASDAQ:OMER) - October 19 at 6:56 PM logoStock Update (NASDAQ:OMER): Omeros Corporation Announces Positive Data from Phase 2 Clinical Trial Evaluating ... - Smarter Analyst (NASDAQ:OMER) - October 19 at 6:56 PM
News IconOmeros Corporation's (OMER) "Buy" Rating Reaffirmed at Cantor Fitzgerald (NASDAQ:OMER) - October 19 at 11:41 AM
News IconOmeros Corporation's (OMER) "Buy" Rating Reiterated at WBB Securities (NASDAQ:OMER) - October 19 at 11:41 AM logoOmeros Announces Positive Data from Phase 2 Clinical Trial Evaluating PPAR-gamma Agonist in Cocaine Abuse (NASDAQ:OMER) - October 19 at 11:41 AM logoOmeros' cocaine addiction candidate shows positive results in mid-stage study; shares up 8% premarket (NASDAQ:OMER) - October 19 at 8:49 AM logo16 Stocks Moving In Wednesday's Pre-Market Session (NASDAQ:OMER) - October 19 at 8:49 AM logoSelling The News In Omeros - Benzinga (NASDAQ:OMER) - October 18 at 6:29 PM logoEPS Target Of Omeros Corporation (NASDAQ:OMER) At $-0.3? - Stocks Daily (NASDAQ:OMER) - October 18 at 6:29 PM
News IconEarnings Analysis & Update for Omeros Corporation (NASDAQ:OMER)? - CSZ News (NASDAQ:OMER) - October 18 at 6:29 PM
News IconScorching Hot Biotech Stocks Tape: Alnylam Pharmaceuticals, Inc. (ALNY), Omeros Corporation (OMER) - The Independent Republic (NASDAQ:OMER) - October 18 at 6:29 PM logoEncouraging News From Omeros Corporation - Seeking Alpha (NASDAQ:OMER) - October 18 at 6:29 PM logoOmeros announces kidney drug trial results, seeks fast-track FDA approval (NASDAQ:OMER) - October 18 at 6:29 PM logoOmeros : Biotech Review DVAX Vaccine Faces Crucial PDUFA Date, CLDX Seeks Fast-Track Orphan Drug Status (NASDAQ:OMER) - October 18 at 11:54 AM logoEncouraging News From Omeros Corporation (NASDAQ:OMER) - October 18 at 11:54 AM logoDoes Omeros Corporation (NASDAQ:OMER)’s Kidney Drug Have A Future? (NASDAQ:OMER) - October 18 at 11:54 AM
News IconUpsurge Transpiring Pre-Market for Shares of Omeros Corporation (NASDAQ:OMER) - CSZ News (NASDAQ:OMER) - October 17 at 6:30 PM
News IconStock Scrambling Higher Mid-session: Omeros Corporation (NASDAQ:OMER) - CSZ News (NASDAQ:OMER) - October 17 at 6:30 PM logoOmeros Renal Drug Shows Promise in Phase II (OMER) (NASDAQ:OMER) - October 17 at 6:30 PM
News IconOmeros Corporation (OMER) Stock: Gaining On Positive Study Results (NASDAQ:OMER) - October 17 at 3:12 PM
News IconGlobal Glomerulonephritis Pipeline H2 2016 Review in Market Report (NASDAQ:OMER) - October 17 at 11:44 AM logoOmeros (OMER): Reiterating $21 PT On Solid Prelim Phase II Data - Cantor Fitzgerald (NASDAQ:OMER) - October 17 at 11:44 AM logoBuzz Stocks: SUPERVALU INC., Bank of America Corp, and Omeros Corporation (NASDAQ:OMER) - October 17 at 11:44 AM logo7:03 am Omeros announces 'positive' data from its Phase 2 clinical trial of OMS721 for the treatment of kidney disorders; 'Statistical significance was achieved on key endpoints of improvement in renal function' (NASDAQ:OMER) - October 17 at 11:44 AM logoOmeros Announces Positive Data from OMS721 Phase 2 Clinical Trial in Renal Diseases (NASDAQ:OMER) - October 17 at 11:44 AM logoOmeros' lead product candidate successful in mid-stage study in kidney diseases; shares ahead 20% premarket (NASDAQ:OMER) - October 17 at 10:12 AM logoOmeros Stock Lifted By Positive Phase 2 Clinical Data (NASDAQ:OMER) - October 17 at 9:49 AM
News IconOhr Pharmaceuticals, Inc. (OHRP) Updated Broker Price Targets (NASDAQ:OMER) - October 16 at 10:56 AM logoMid-Day Market Update: Advanced Micro Devices Climbs After Chip Deal With Alibaba; Ocean Power Technologies Shares Slide (NASDAQ:OMER) - October 14 at 1:36 PM logoMid-Afternoon Market Update: Crude Oil Down Over 1%; VOXX Shares Spike Higher (NASDAQ:OMER) - October 12 at 4:51 PM
News IconOmeros Corporation (OMER) Updated Broker Price Targets - The De Soto Edge (NASDAQ:OMER) - October 12 at 11:59 AM
News IconInsiders are Curtailing Holdings in Omeros Corporation (NASDAQ:OMER) - CSZ News (NASDAQ:OMER) - October 12 at 11:59 AM
News IconConsensus Take: Omeros Corporation (NASDAQ:OMER) Earnings & Ratings Watch - CSZ News (NASDAQ:OMER) - October 12 at 11:59 AM
News IconBroker Roundup For Omeros Corporation (OMER) - The De Soto Edge (NASDAQ:OMER) - October 9 at 10:48 AM
News IconAnalyst Coverage: Omeros Corporation (OMER) - NewsDen (NASDAQ:OMER) - October 7 at 11:42 AM logoCan Omeros Corporation (NASDAQ:OMER) Outdo Analysts EPS Target Of $-0.3? - Stocks Daily (NASDAQ:OMER) - October 6 at 6:23 PM logoAnxiety Disorders Pipeline 2016 Market Key Companies Analysis Research (NASDAQ:OMER) - October 6 at 12:03 PM logoGilead Executives Might Think Small (NASDAQ:OMER) - October 6 at 12:03 PM
News IconCommit To Purchase Omeros Corp At $8, Earn 18.2% Annualized Using Options (NASDAQ:OMER) - October 6 at 12:03 PM


Omeros Corporation (NASDAQ:OMER) Chart for Monday, October, 24, 2016

Last Updated on 10/24/2016 by Staff